laquinimod topical (TV-5600) / Active Biotech - LARVOL DELTA

Safety and Biodistribution of Topical Laquinimod, an Immunomodulator Targeting Aryl Hydrocarbon Receptor: The LION Study. (PubMed, Ophthalmol Sci) - P1 | "These findings support investigation of LAQ's therapeutic potential for inflammatory eye diseases. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Inflammation • Ophthalmology

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Quan Dong Nguyen | Trial completion date: Apr 2025 ➔ Jul 2025 | Trial primary completion date: Jan 2025 ➔ Jul 2025

Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Quan Dong Nguyen | Trial completion date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2024

Immunomodulating • Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Quan Dong Nguyen | Not yet recruiting ➔ Recruiting

Enrollment open • Immunomodulating • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

LION: Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops : a Phase 1 Study (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Quan Dong Nguyen

Immunomodulating • New P1 trial • Ocular Inflammation • Ophthalmology • Uveitis

A Study of Laquinimod Eye-drops in Healthy Participants (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Active Biotech AB | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

A Study of Laquinimod Eye-drops in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Active Biotech AB | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

A Study of Laquinimod Eye-drops in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Active Biotech AB | N=42 ➔ 56 | Trial completion date: Jun 2022 ➔ Mar 2023 | Trial primary completion date: May 2022 ➔ Jan 2023

Enrollment change • Trial completion date • Trial primary completion date • Ophthalmology

A Study of Laquinimod Eye-drops in Healthy Participants (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Active Biotech AB

Clinical • New P1 trial • Ophthalmology